Discover
MIST
Milestone Pharmaceuticals Inc.
1.32
2 x 0.97
2 x 1.68
bid
ask
-
0.02
1.49%
2 @ 04:00 PM
1.31 -0.01 (0.61%)
| Ytd | -34.65% | |
| 1y | -29.79% |
1.31
day range
1.35
1.00
52 week range
3.06
| Open | 1.35 | Prev Close | 1.34 | Low | 1.31 | High | 1.35 | Mkt Cap | 164.34M |
| Vol | 1.01M | Avg Vol | 1.78M | EPS | -0.64 | P/E | N/A | Forward P/E | -2.15 |
| Beta | 1.73 | Short Ratio | 2.46 | Inst. Own | 57.01% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-12 | 50-d Avg | 1.53 | 200-d Avg | 1.84 | 1yr Est | 10.25 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.16 | -0.14 | 0.02 | 12.50% |
| 2024-08-08 | 2024-06 | -0.19 | -0.14 | 0.05 | 26.32% |
| 2024-08-08 | 2024-06 | -0.19 | N/A | N/A | N/A |
| 2024-05-13 | 2024-03 | -0.26 | -0.21 | 0.05 | 19.23% |
| 2024-05-13 | 2024-03 | -0.26 | N/A | N/A | N/A |
| 2024-03-21 | 2023-12 | -0.3 | -0.32 | -0.02 | -6.67% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-10-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-22 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-22 | Rodman & Renshaw | Upgrade | Buy | |
| 2024-07-01 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-30 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-05-16 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Blackrock Inc. | 4.97M | 9.20M | 9.32% |
| 2024-09-29 | RTW Investments LP | 3.26M | 6.02M | 6.11% |
| 2024-09-29 | Millennium Management Llc | 2.78M | 5.14M | 5.21% |
| 2024-09-29 | Alta Fundamental Advisers LLC | 2.66M | 4.92M | 4.99% |
| 2024-09-29 | Citadel Advisors Llc | 2.06M | 3.81M | 3.87% |
| 2024-09-29 | Orbimed Advisors LLC. | 2.00M | 3.70M | 3.75% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | SPDR (R) Idx Shares-SPDR (R) S&P (R) International Small Cap ETF | 19.31K | 35.73K | 0.04% |
| 2024-10-30 | Fidelity NASDAQ Composite Index Fund | 17.58K | 32.52K | 0.03% |
| 2024-09-29 | JNL Series Trust-JNL/DFA U.S. Small Cap Fund | 1.66K | 3.07K | 0.00% |